Drug Profile

706 - 3SBio

Alternative Names: 706 anti-PD1/PD-L1 Bispecific antibody; 706 anti-PD1/PD-L1 BsAb; 706-3SBio

Latest Information Update: 17 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 3SBio
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 Sep 2025 Shenyang Sunshine Pharmaceutical plans a phase II trial for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in China in September 2025 (Parenteral) (NCT07171606)
01 Aug 2024 Sunshine Guojian Pharmaceutical plans a phase I trial for Solid tumors in August 2024 (NCT06533605)
30 Apr 2024 Preclinical development is ongoing in China (Sunshine Guojian Pharmaceutical pipeline, April 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com